Differences in the in vitro susceptibility of planktonic and biofilm-associated Escherichia coli strains to antimicrobial agents

Journal of Chemotherapy

Volumn 22, Issue 5, 2010, Pages 312-317

  Naves, P ^a,b   Del Prado, G ^a   Ponte, C ^a   Soriano, F ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Lab de Blodiversidade do Cerrado   (Brazil)

Author keywords

Alamar Blue assay; Biofilm; Escherichia coli; In vitro susceptibility; Planktonic

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFOTAXIME; CIPROFLOXACIN; GENTAMICIN; POLYSTYRENE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTERIUM ISOLATION; BIOFILM; BROTH DILUTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; ESCHERICHIA COLI; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PLANKTON COUNTER;

EID: 78651397723     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.5.312     Document Type: Article

References (28)

1. Pettit RK, Weber CA, Kean MJ, Hoffmann H, Pettit GR, Tan R et al. Microplate Alamar Blue Assay for Staphylococcus epidermidis biofilm susceptibility testing. Antimicrob Agents Chemother 2005; 49 (7): 2612-2617.
2. Flemming K, Klingenberg C, Cavanagh JP, Setteng M, Stensen W, Svendsen JS, Flægstad T. High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. J Antimicrob Chemother 2009; 63 (1): 136-145.
3. Lindsay D, von Holy A. Bacterial biofilms within the clinical setting: what healthcare professionals should know. J Hosp Infect 2008; 64 (4): 313-325.
4. Reisner A, Krogfelt KA, Klein BM, Zechner EL, Molin S. In vivo biofilm formation of commensal and pathogenic Escherichia coli strains: Impact of environmental and genetic factors. J Bacteriol 2006; 188 (10): 3572-3581.
5. Sauer K, Rickard AH, Davies DG. Biofilm and biocomplexity. Microbe 2007; 2 (7): 347-353.
6. Beloin C, Roux A, Ghigo JM. Escherichia coli biofilms. In: Romeo T, Ed. Bacterial biofilms. Curr Top Microbiol Immun 2008; 322: 249-289.
7. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15 (2): 167-193.
8. Aslam S. Effect of antibacterials on biofilms. Am J Infect Control. 2008; 36 (10): S175e9-S175e11.
9. Anwar H, Costerton JW. Effective use of antibiotics in the treatment of biofilm-associated infections. ASM News 1992; 58 (12): 665-668.
10. Sedlacek MJ, Walker C. Antibiotic resistance in an in vitro subgingival biofilm model. Oral Microbiol Immunol 2007; 22 (5): 333-339.
11. Jiang X, Pace JL. Microbial biofilms In: Pace JL, Rupp M, Finch RG, Eds. Biofilms, infection, and antimicrobial therapy. Cleveland, USA: CRC Press. 2006: 3-19.
12. Naves P, del Prado G, Huelves L, Gracia M, Ruiz V, Blanco J et al. Correlation between virulence factors and in vitro biofilm formation by Escherichia coli strains. Microb. Pathogen. 2008; 45 (2): 86-91.
13. th Informational Supplement. CLSI document M100-S16. CLSI, Wayne, Pennsylvania, USA, 2006.
14. Repp KK, Menor SA, Pettit KK. Microplate Alamar Blue Assay for susceptibility testing of Candida albicans biofilms. Med Mycol 2007; 45 (7): 603-607.
15. Soriano F, García-Corbeira P, Ponte C, Fernández-Roblas R, Gadea I. Correlation of pharmacodynamic parameters of five α-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother 1996; 40(12): 2686-2690.
16. Minardi D, Montanari MP, Tili E, Cochetti I, Mingoia M, Varaldo PE et al. Effects of fluoroquinolones on bacterial adhesion and on preformed biofilm of strains isolated from urinary double J stents. J Chemotherapy 2008; 20(2): 195-201.
17. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 2002; 66 (2): 86-92.
18. Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A, Lomovskaya O, Plésiat P. MexXY-OprM efflux pump is necessary for adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 2003; 47 (4): 1371-1375.
19. Zeiler HJ, Grohe K. The in vitro and in vivo activity of ciprofloxacin . Eur J Clin Microbiol 1984; 3 (4): 339-343.
20. Simmen H-P, Battaglia H, Kossmann T, Blaser J. Effect of peritoneal fluid pH on outcome of aminoglycoside treatment of intraabdominal infections 1993; 17 (3): 393-397.
21. Walters III MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47 (1): 317-323.
22. Kumon H, Tomochika K, Matunaga T, Ogawa M, Ohmori H. A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol 1994; 38 (8): 615-619.
23. Shigeta M, Tanaka G, Komatsuzawa H, Sugai M, Suginaka H, Usui T. Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: a simple method. Chemotherapy 1997; 43 (5): 340-345. (Pubitemid 27346061)
24. Gordon CA, Hodges NA, Marriott C. Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis derived Pseudomonas aeruginosa. J Antimicrob Chemother 1988; 22 (5): 667-674.
25. Nichols WW, Dorrington SM, Slack MPE, Walmsley HL. Inhibition of tobramycin diffusion by binding to alginate. Antimicrob Agents Chemother 1988; 32 (4): 518-523.
26. Reid G, Habash M, Vachon D, Denstedt J, Riddell J, Beheshti M. Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation. Int J Antimicrob Agents 2001; 17 (4): 317-320.
27. Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27 (3): 196-200.
28. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofims. Lancet 2001; 358 (9276): 135-138.